Clinical Trial Update: Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia

View source ↗

Summary

This clinical trial update reports on the completed study evaluating XCL1 as a prognostic biomarker in acute lymphoblastic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Snippet

Sponsor: Hospital Universitario Dr. Jose E. Gonzalez | Conditions: Acute Lymphoblastic Leukemia | Status: COMPLETED